MedTrace Logo

An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas

NCT05011058 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 102

Last updated 2025-07-28

Study results available
· View outcomes & findings →

Summary

A Phase 2 study to evaluate the efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive lymphomas

Conditions

  • Epstein-Barr Virus Associated Lymphoma
  • EBV-Positive DLBCL, NOS
  • EBV-Related Non-Hodgkin Lymphoma
  • EBV Related PTCL, NOS
  • EBV-Related Hodgkin Lymphoma
  • EBV-Related PTLD
  • EBV-Related Lymphoproliferative Disorder

Interventions

DRUG

Nanatinostat in combination with valganciclovir

Drug: Nanatinostat, 20 mg orally once daily, 4 days per week in 28 day cycles Drug: Valganciclovir, 900 mg orally once daily in 28 day cycles

Sponsors & Collaborators

  • Viracta Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Darrel P Cohen, MD, PhD · Viracta Therapeutics

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-28
Primary Completion
2024-12-26
Completion
2025-01-31
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Brazil
  • Canada
  • France
  • Germany
  • Israel
  • Italy
  • Malaysia
  • Singapore
  • South Korea
  • Spain
  • Taiwan
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05011058 on ClinicalTrials.gov